ESMO-Magnitude of Clinical Benefit Scale

The ESMO-MCBS is a standardised, generic, validated tool to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies at the time of approval.

The below filter has been created to provide a centralised location of cancer medicines that have been scored using ESMO-MCBS v1.1 and published by ESMO.

ESMO-MCBS grading

Curative setting grading - A (major benefit), B (important benefit), C (minor benefit):

  • Form 1   - For new approaches to adjuvant therapy or new potentially curative therapies

Non-curative setting grading - 5 and 4 (substantial benefit), 3 (moderate benefit), 2 and 1 (negligible benefit):

  • Form 2a   - For therapies that are not likely to be curative with primary endpoint of OS 
  • Form 2b   - For therapies that are not likely to be curative with primary endpoint PFS 
  • Form 2c   - For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies 
  • Form 3     - For single-arm studies in “orphan diseases” and for diseases with “high unmet need” when primary outcome is PFS or ORR 

For full information please click here

The ESMO-MCBS Score Card

The ESMO-MCBS Score Card allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.

OR
OR
Tested Agent Combined Agent(s) Control Arm Treatment Setting Tumour Type Tumour Sub-type Tumour Sub-group Tumour Stage Score Ref. Score
Card
Trastuzumab Chemotherapy Adjuvant or neo-adjuvant HER2 positive tumours Breast Cancer Breast Cancer HER2+ Early
A
Piccart-Gebhart et al, N Engl J Med 2005; 353:1659-1672 Icon to see scorecard 1 1
Pertuzumab Trastuzumab + docetaxel Trastuzumab + docetaxel (Randomised phase II study) Neo-adjuvant HER2 overexpressed invasive ductal breast Breast Cancer Breast Cancer HER2+ Early
C
Gianni et al, Lancet Oncol 2012; 13:25-32
Gianni et al, Lancet Oncol 2016; 17:791-800
Icon to see scorecard 2 1
T-DM1 Lapatinib + capecitabine 2nd line metastatic after trastuzumab failure (extensive crossover) Breast Cancer Breast Cancer HER2+ Metastatic
4
Verma et al, N Engl J Med 2012; 367: 1783-1791
Welslau et al, Cancer 2014; 120: 642-651
Icon to see scorecard 3 1
Pertuzumab Trastuzumab + docetaxel Trastuzumab + docetaxel + placebo 1st line metastatic Breast Cancer Breast Cancer HER2+ Metastatic
4
Swain et al, N Engl J Med 2015; 372:724-734
Baselga et al, N Engl J Med 2012; 366:109-119
Cortes et al, Ann Oncol 2013; 24:2630-2635
Icon to see scorecard 4 1
Trastuzumab Lapatinib Lapatinib 3rd line metastatic Breast Cancer Breast Cancer HER2+ Metastatic
4
Blackwell et al, J Clin Oncol 2012; 30:2585-2592 Icon to see scorecard 5 1
Palbociclib Fulvestrant Fulvestrant + placebo 2nd line metastatic HR+ HER2- Breast Cancer Breast Cancer HR+ HER2- Metastatic
4
Cristofanilli et al, Lancet Oncol 2016; 17:425-439 Icon to see scorecard 6 1
Palbociclib Letrozole Letrozole + placebo 1st line metastatic HR+ HER2- Breast Cancer Breast Cancer HR+ HER2- Metastatic
3
Finn et al, N Engl J Med 2016; 375:1925-1936 Icon to see scorecard 7 1
Palbociclib Letrozole Letrozole (Randomised phase II study) 1st line metastatic HR+ HER2- Breast Cancer Breast Cancer HR+ HER2- Metastatic
3
Finn et al, Lancet Oncol 2015; 16:25-35 Icon to see scorecard 8 1
Ribociclib Letrozole Letrozole + placebo 1st line metastatic post-menopause HR+ HER2- Breast Cancer Breast Cancer HR+ HER2- Metastatic
3
Hortobagyi et al, Ann Oncol 2018; 29:1541-1547 Icon to see scorecard 9 1
Lapatinib Capecitabine Capecitabine 2nd line metastatic after trastuzumab failure Breast Cancer Breast Cancer HER2+ Metastatic
3
Geyer et al, N Engl J Med 2006; 355:2733-2743 Icon to see scorecard 10 1